FDA GIVES NDMA GREEN LIGHT TO BEGIN ATTAPULGITE, PPA STUDIES
This article was originally published in The Tan Sheet
Executive Summary
FDA GIVES NDMA GREEN LIGHT TO BEGIN ATTAPULGITE, PPA STUDIES in two letters sent to the association in June. However, while the Nonprescription Drag Manufacturers Association and FDA are in agreement on the final protocol for the phenylpropanolamine study, FDA recommended several changes in the attapulgite protocol related to efficacy endpoints.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning